



Prep Rinse the soft and flexible applicator with hot water. Shake off the excess. Pick up LACRISERT® (hydroxypropyl cellulose ophthalmic insert) by lightly touching it with the grooved tip of the applicator.

3 Simple Steps for Placement




Pocket

Gently grasp the outer corner of the lower eyelid between your thumb and index finger and pull out to create a “pocket”.



Place

Place LACRISERT® by gently brushing it on the inside of the “pocket”.



Pull up and over

Pull the lower lid up and over the LACRISERT®, then release. Allow LACRISERT® to settle comfortably in the “pocket”.

Application Tips

- Add a drop or two of artificial tears after placement to expedite softening¹
- Put contact lens in first, then place LACRISERT®
- If using makeup, put makeup on first, then place LACRISERT®
- LACRISERT® may be used at night or in the morning¹



LACRISERT® is soluble, and begins to soften.



As LACRISERT® dissolves throughout the day, it provides continuous lubrication and protection.


LACRISERT®
(hydroxypropyl cellulose ophthalmic insert)

Once a Day*²
Slow-release Artificial Tear^{1,3-5}
for Continuous Lubrication

Please see Important Safety Information on back.




Incorrect Placement

LACRISERT® shouldn't touch the white part of the eye or be visible on the rim of the lower lid.



Correct Placement

LACRISERT® should rest in the pink part under the lower eyelid.



When placed correctly, it should be completely out of sight and feel comfortable. **LACRISERT® acts like a slow-release artificial tear to help provide ongoing lubrication and protection.**

References: 1. Lamberts DW, Langston DP, Chu W. A clinical study of slow-releasing artificial tears. *Ophthalmology*. 1978;85(8):794-800. 2. LACRISERT package insert [Aton Pharma, Madison NJ]. 3. Katz IM, Blackman WM. A soluble-sustained release ophthalmic delivery unit. *Am J Ophthalmol*. 1977;5(8):728-734. 4. Breslin CW, Katz J, Kaufman HE, Katz I. Slow release artificial tears. In: *Leopold IH, Burns RF, eds. Symposium on ocular therapy*. New York: Wiley, 1977;10:77-83. 5. Hovding G, Aasved H. Slow-release artificial tears (SRAT) in dry eye disease. *Acta Ophthalmol (Kbh)*. 1981;59:842-6.

Please see Prescribing Information that accompanies your prescription.

* In most patients, one LACRISERT® placed into each eye, once daily, is effective in providing all-day symptom relief. Some patients may require twice-daily use for optimal results.

BAUSCH + LOMB

Lacrisert is a trademark of Valeant Pharmaceuticals International or its affiliates.
Bausch + Lomb is a trademark of Bausch & Lomb Incorporated or its affiliates.
©2014 Bausch & Lomb Incorporated.

Indications and Usage

LACRISERT® (hydroxypropyl cellulose ophthalmic insert) is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. LACRISERT® is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT® is also indicated for patients with exposure keratitis, decreased corneal sensitivity, and recurrent corneal erosions.

Important Safety Information

- LACRISERT® (hydroxypropyl cellulose ophthalmic insert) is contraindicated in patients who are hypersensitive to hydroxypropyl cellulose.
- Instructions for inserting and removing LACRISERT® should be carefully followed.
- If improperly placed, LACRISERT® may result in corneal abrasion. Because LACRISERT® may cause transient blurred vision, patients should be instructed to exercise caution when driving or operating machinery.
- The following adverse reactions have been reported, but were in most instances mild and temporary: transient blurring of vision, ocular discomfort or irritation, matting or stickiness of eyelashes, photophobia, hypersensitivity, eyelid edema, and hyperemia.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

Please see accompanying full Prescribing Information, including Instructions for Use.


For more information on LACRISERT®, plus FREE samples and coupons, go to www.LACRISERT.com


LACRISERT®
(hydroxypropyl cellulose ophthalmic insert)
Once a Day*²
Slow-release Artificial Tear^{1,3-5}
for Continuous Lubrication

LACRISERT®**(hydroxypropyl cellulose ophthalmic insert)****DESCRIPTION**

LACRISERT® (hydroxypropyl cellulose ophthalmic insert) is a sterile, translucent, rod-shaped, water soluble, ophthalmic insert made of hydroxypropyl cellulose, for administration into the inferior cul-de-sac of the eye.

The chemical name for hydroxypropyl cellulose is cellulose, 2-hydroxypropyl ether. It is an ether of cellulose in which hydroxypropyl groups (-CH₂CHOHCH₃) are attached to the hydroxyls present in the anhydroglucose rings of cellulose by ether linkages. A representative structure of the monomer is:



The molecular weight is typically 1×10^6 .

Hydroxypropyl cellulose is an off-white, odorless, tasteless powder. It is soluble in water below 38°C, and in many polar organic solvents such as ethanol, propylene glycol, dioxane, methanol, isopropyl alcohol (95%), dimethyl sulfoxide, and dimethyl formamide.

Each LACRISERT is 5 mg of hydroxypropyl cellulose. LACRISERT contains no preservatives or other ingredients. It is about 1.27 mm in diameter by about 3.5 mm long.

LACRISERT is supplied in packages of 60 units, together with illustrated instructions and a special applicator for removing LACRISERT from the unit dose blister and inserting it into the eye. A spare applicator is included in each package.

CLINICAL PHARMACOLOGY*Pharmacodynamics*

LACRISERT acts to stabilize and thicken the precorneal tear film and prolong the tear film breakup time which is usually accelerated in patients with dry eye states. LACRISERT also acts to lubricate and protect the eye.

LACRISERT usually reduces the signs and symptoms resulting from moderate to severe dry eye syndromes, such as conjunctival hyperemia, corneal and conjunctival staining with rose bengal, exudation, itching, burning, foreign body sensation, smarting, photophobia, dryness and blurred or cloudy vision. Progressive visual deterioration which occurs in some patients may be retarded, halted, or sometimes reversed.

In a multicenter crossover study the 5 mg LACRISERT administered once a day during the waking hours was compared to artificial tears used four or more times daily. There was a prolongation of tear film breakup time and a decrease in foreign body sensation associated with dry eye syndrome in patients during treatment with inserts as compared to artificial tears; these findings were statistically significantly different between the treatment groups. Improvement, as measured by amelioration of symptoms, by slit lamp examination and by rose bengal staining of the cornea and conjunctiva, was greater in most patients with moderate to severe symptoms during treatment with LACRISERT. Patient comfort was usually better with LACRISERT than with artificial tears solution, and most patients preferred LACRISERT.

In most patients treated with LACRISERT for over one year, improvement was observed as evidenced by amelioration of symptoms generally associated with keratoconjunctivitis sicca such as burning, tearing, foreign body sensation, itching, photophobia and blurred or cloudy vision.

During studies in healthy volunteers, a thickened precorneal tear film was usually observed through the slit-lamp while LACRISERT was present in the conjunctival sac.

Pharmacokinetics and Metabolism

Hydroxypropyl cellulose is a physiologically inert substance. In a study of rats fed hydroxypropyl cellulose or unmodified cellulose at levels up to 5% of their diet, it was found that the two were biologically equivalent in that neither was metabolized.

Studies conducted in rats fed ¹⁴C-labeled hydroxypropyl cellulose demonstrated that when orally administered, hydroxypropyl cellulose is not absorbed from the gastrointestinal tract and is quantitatively excreted in the feces.

Dissolution studies in rabbits showed that hydroxypropyl cellulose inserts became softer within 1 hour after they were placed in the conjunctival sac. Most of the inserts dissolved completely in 14 to 18 hours; with a single exception, all had disappeared by 24 hours after insertion. Similar dissolution of the inserts was observed during prolonged administration (up to 54 weeks).

INDICATIONS AND USAGE

LACRISERT is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. LACRISERT is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions.

LACRISERT is also indicated for patients with:

- Exposure keratitis
- Decreased corneal sensitivity
- Recurrent corneal erosions

CONTRAINDICATIONS

LACRISERT is contraindicated in patients who are hypersensitive to hydroxypropyl cellulose.

WARNINGS

Instructions for inserting and removing LACRISERT should be carefully followed.

PRECAUTIONS*General*

If improperly placed, LACRISERT may result in corneal abrasion (see DOSAGE AND ADMINISTRATION). *Information for Patients*

Patients should be advised to follow the instructions for using LACRISERT which accompany the package.

Because this product may produce transient blurring of vision, patients should be instructed to exercise caution when operating hazardous machinery or driving a motor vehicle.

Drug Interactions

Application of hydroxypropyl cellulose ophthalmic inserts to the eyes of unanesthetized rabbits immediately prior to or two hours before instilling pilocarpine, proparacaine HCl (0.5%), or phenylephrine (5%) did not markedly alter the magnitude and/or duration of the miotic, local corneal anesthetic, or mydriatic activity, respectively, of these agents. Under various treatment schedules, the anti-inflammatory effect of ocularly instilled dexamethasone (0.1%) in unanesthetized rabbits with primary uveitis was not affected by the presence of hydroxypropyl cellulose inserts.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Feeding of hydroxypropyl cellulose to rats at levels up to 5% of their diet produced no gross or histopathologic changes or other deleterious effects.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

Geriatric Use

No overall differences in safety or effectiveness have been observed between elderly and younger patients.

ADVERSE REACTIONS

The following adverse reactions have been reported in patients treated with LACRISERT, but were in most instances mild and transient:

- Transient blurring of vision (See PRECAUTIONS)
- Ocular discomfort or irritation
- Matting or stickiness of eyelashes
- Photophobia
- Hypersensitivity
- Edema of the eyelids
- Hyperemia

DOSAGE AND ADMINISTRATION

One LACRISERT ophthalmic insert in each eye once daily is usually sufficient to relieve the symptoms associated with moderate to severe dry eye syndromes. Individual patients may require more flexibility in the use of LACRISERT; some patients may require twice daily use for optimal results.

Clinical experience with LACRISERT indicates that in some patients several weeks may be required before satisfactory improvement of symptoms is achieved.

LACRISERT is inserted into the inferior cul-de-sac of the eye beneath the base of the tarsus, not in apposition to the cornea, nor beneath the eyelid at the level of the tarsal plate. If not properly positioned, it will be expelled into the interpalpebral fissure, and may cause symptoms of a foreign body. Illustrated instructions are included in each package. While in the licensed practitioner's office, the patient should read the instructions, then practice insertion and removal of LACRISERT until proficiency is achieved.

NOTE: Occasionally LACRISERT is inadvertently expelled from the eye, especially in patients with shallow conjunctival fornices. The patient should be cautioned against rubbing the eye(s) containing LACRISERT, especially upon awakening, so as not to dislodge or expel the insert. If required, another LACRISERT ophthalmic insert may be inserted. If experience indicates that transient blurred vision develops in an individual patient, the patient may want to remove LACRISERT a few hours after insertion to avoid this. Another LACRISERT ophthalmic insert maybe inserted if needed.

If LACRISERT causes worsening of symptoms, the patient should be instructed to inspect the conjunctival sac to make certain LACRISERT is in the proper location, deep in the inferior cul-de-sac of the eye beneath the base of the tarsus. If these symptoms persist, LACRISERT should be removed and the patient should contact the practitioner.

HOW SUPPLIED

LACRISERT, a sterile, translucent, rod-shaped, water-soluble, ophthalmic insert made of hydroxypropyl cellulose, 5 mg, is supplied as follows:

NDC 25010-805-68 in packages containing 60 unit doses (each wrapped in an aluminum blister), two reusable applicators, and a plastic storage container to store the applicators after use.

Storage

Store below 30°C (86°F).

Distributed by:

Bausch + Lomb, a division of
Valeant Pharmaceuticals North America LLC
Bridgewater, NJ 08807 USA

Manufactured by:

DPT Lakewood, Inc.
Lakewood, NJ 08701 USA

LACRISERT is a registered trademark of Valeant Pharmaceuticals International, Inc. or its affiliates.

© Valeant Pharmaceuticals International, Inc.

All rights reserved.

9421400

Rev. 08/14